Drug Search Results

Eltoprazine

Alternative Names: eltoprazine
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: 5-HT1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amarantus BioScience Holdings
Company Location: SAN FRANCISCO CA 94111
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eltoprazine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Parkinson's Disease|Dyskinesias|Cognitive Dysfunction|Schizophrenia

Trial	Phase	Trial Status	Disease	Primary Completion Date
AMBS-ELTO-201	P2	Unknown status	Parkinson's Disease\|Dyskinesias	2017-06-01
2015-000373-13	P2	Temporarily not available	Parkinson's Disease	2016-08-18
PGI12004	P2	Completed	Cognitive Dysfunction\|Schizophrenia	2012-09-01
ELTODYS09	P2	Terminated	Dyskinesias\|Parkinson's Disease	2012-02-17

Recent News Events

Date	Type	Title
10/01/2023	PubMed	Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
04/27/2022	News Article	Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
04/01/2022	PubMed	Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.
09/15/2021	PubMed	Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist.
02/06/2020	News Article	Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
02/06/2020	News Article	CBD's Status Continues to Grow in the Eyes of Consumers
02/04/2020	News Article	Amarantus Releases Letter to Shareholders

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions